{"id":"NCT02021656","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection","officialTitle":"A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-10","primaryCompletion":"2017-07-08","completion":"2017-09-29","firstPosted":"2013-12-27","resultsPosted":"2018-12-28","lastUpdate":"2020-03-05"},"enrollment":384,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic HCV Infection"],"interventions":[{"type":"DRUG","name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]}],"arms":[{"label":"LDV/SOF","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in treatment-naive and treatment-experienced participants with chronic genotype 1 hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"LDV/SOF: China","deltaMin":100,"sd":null},{"arm":"LDV/SOF: Overall","deltaMin":99.2,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":45,"countries":["China","South Korea","Taiwan"]},"refs":{"pmids":["27198664","26841930"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":384},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Headache"]}}